484 related articles for article (PubMed ID: 25260897)
1. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes.
Huang HC; Tao MH; Hung TM; Chen JC; Lin ZJ; Huang C
Antiviral Res; 2014 Nov; 111():100-11. PubMed ID: 25260897
[TBL] [Abstract][Full Text] [Related]
2. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
3. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
Ciesek S; von Hahn T; Colpitts CC; Schang LM; Friesland M; Steinmann J; Manns MP; Ott M; Wedemeyer H; Meuleman P; Pietschmann T; Steinmann E
Hepatology; 2011 Dec; 54(6):1947-55. PubMed ID: 21837753
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice.
Lai YH; Sun CP; Huang HC; Chen JC; Liu HK; Huang C
BMC Complement Altern Med; 2018 Sep; 18(1):248. PubMed ID: 30189898
[TBL] [Abstract][Full Text] [Related]
5. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
6. Strategies to inhibit entry of HBV and HDV into hepatocytes.
Urban S; Bartenschlager R; Kubitz R; Zoulim F
Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
[TBL] [Abstract][Full Text] [Related]
7. Ergosterol peroxide inhibits HBV infection by inhibiting the binding of the pre-S1 domain of LHBsAg to NTCP.
Huang H; Huang HC; Chiou WC; Lin LC; Chen JC; Liu HK; Lai YH; Huang C
Antiviral Res; 2021 Nov; 195():105184. PubMed ID: 34627935
[TBL] [Abstract][Full Text] [Related]
8. Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication.
Qiao L; Sui J; Luo G
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232184
[TBL] [Abstract][Full Text] [Related]
9. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro.
Xu J; Wang J; Deng F; Hu Z; Wang H
Antiviral Res; 2008 Jun; 78(3):242-9. PubMed ID: 18313149
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
[TBL] [Abstract][Full Text] [Related]
11. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
Li J; Zong L; Sureau C; Barker L; Wands JR; Tong S
J Virol; 2016 Sep; 90(18):8302-13. PubMed ID: 27384660
[TBL] [Abstract][Full Text] [Related]
12. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
[TBL] [Abstract][Full Text] [Related]
13. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
Watashi K; Sluder A; Daito T; Matsunaga S; Ryo A; Nagamori S; Iwamoto M; Nakajima S; Tsukuda S; Borroto-Esoda K; Sugiyama M; Tanaka Y; Kanai Y; Kusuhara H; Mizokami M; Wakita T
Hepatology; 2014 May; 59(5):1726-37. PubMed ID: 24375637
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 inhibits HBV entry through NTCP down regulation.
Bouezzedine F; Fardel O; Gripon P
Virology; 2015 Jul; 481():34-42. PubMed ID: 25765005
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide.
Le C; Sirajee R; Steenbergen R; Joyce MA; Addison WR; Tyrrell DL
Viruses; 2021 Jan; 13(1):. PubMed ID: 33445753
[TBL] [Abstract][Full Text] [Related]
17. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG
Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
[TBL] [Abstract][Full Text] [Related]
19. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
[TBL] [Abstract][Full Text] [Related]
20. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
Wang XJ; Hu W; Zhang TY; Mao YY; Liu NN; Wang SQ
Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
